Discover the latest breakthroughs in oncology, including pivotal FDA decisions, promising therapies, and new treatment ...

While androgen receptor (AR) inhibitors have long been a cornerstone in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC), the ARANOTE trial (NCT04736199) sets darolutamide (Nubeqa ...

The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, ...

A phase 2 trial shows promising safety results for carotuximab in treating advanced prostate cancer, offering hope for ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

An expert discusses how the EPO-PRETAR trial results showed no significant difference in transfusion dependence between early ...

An expert discusses how long-term follow-up data from the COMMANDS trial demonstrated sustained superiority of luspatercept ...

Zenith Epigenetics' ZEN-3694 gains FDA fast track designation, offering hope for patients with aggressive NUT carcinoma ...

Immunotherapy shows promise in reducing recurrence rates for high-risk skin cancer, despite mixed results in recent clinical ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Emiltatug ledadotin shows promising antitumor activity in various cancers, with manageable safety, highlighting its potential ...

Jacob E. Berchuck, MD, highlights novel findings pointing to androgen receptor signaling and Wnt pathway activation as key correlates of poor response to therapy.